Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia.

[1]  E. Hoffman,et al.  Ammonia Myocardial Imaging at Rest and With Exercise in Normal Volunteers Quantification of Absolute Myocardial Perfusion With Dynamic Positron Emission Tomography , 2005 .

[2]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[3]  T. Lehtimäki,et al.  Effect of Lipid-Lowering Therapy with Pravastatin on Myocardial Blood Flow in Young Mildly Hypercholesterolemic Adults , 2001, Journal of cardiovascular pharmacology.

[4]  K. Ohtomo,et al.  Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance , 2001, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[5]  K. Ohtomo,et al.  Coronary microangiopathy in type 2 diabetic patients: relation to glycemic control, sex, and microvascular angina rather than to coronary artery disease. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  U. Laufs,et al.  Direct vascular effects of HMG-CoA reductase inhibitors. , 2000, Trends in cardiovascular medicine.

[7]  F. Bernini,et al.  Pleiotropic effects of statins in atherosclerosis and diabetes. , 2000, Diabetes care.

[8]  K. Ohtomo,et al.  Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. , 1999, Circulation.

[9]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[10]  B. Kasiske,et al.  Lipophilic statins induce apoptosis of human vascular smooth muscle cells. , 1999, Kidney international. Supplement.

[11]  U. Gleichmann,et al.  Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. , 1999, Circulation.

[12]  M. Schwaiger,et al.  Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. , 1999, Circulation.

[13]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[14]  K. Gould.  Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine. , 1998, The American journal of cardiology.

[15]  M. Pfeffer,et al.  Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. , 1998, Journal of the American College of Cardiology.

[16]  M. Omata,et al.  Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. , 1998, Journal of the American College of Cardiology.

[17]  MasaoOmata,et al.  Altered Myocardial Vasodilatation in Patients With Hypertriglyceridemia in Anatomically Normal Coronary Arteries , 1998 .

[18]  T. Ohtake,et al.  Hyperglycemia Rather Than Insulin Resistance Is Related to Reduced Coronary Flow Reserve in NIDDM , 1998, Diabetes.

[19]  P. Shah,et al.  Lipid lowering versus revascularization: an idea whose time (for testing) has come. , 1997, Circulation.

[20]  M. Omata,et al.  Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. , 1996, Circulation.

[21]  M. Omata,et al.  Reduced coronary flow reserve in familial hypercholesterolemia. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  J. Viikari,et al.  Coronary flow reserve is impaired in young men with familial hypercholesterolemia. , 1996, Journal of the American College of Cardiology.

[23]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[24]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[25]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[26]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[27]  O Muzik,et al.  Early Detection of Abnormal Coronary Flow Reserve in Asymptomatic Men at High Risk for Coronary Artery Disease Using Positron Emission Tomography , 1994, Circulation.

[28]  P. Touboul,et al.  Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.

[29]  A. Nitenberg,et al.  Impairment of Coronary Vascular Reserve and ACh-Induced Coronary Vasodilation in Diabetic Patients With Angiographically Normal Coronary Arteries and Normal Left Ventricular Systolic Function , 1993, Diabetes.

[30]  S S Gambhir,et al.  Quantification of Regional Myocardial Blood Flow Using 13N‐Ammonia and Reoriented Dynamic Positron Emission Tomographic Imaging , 1992, Circulation.

[31]  K. Gould,et al.  Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. , 1992, The American journal of cardiology.

[32]  K. Gould.  Clinical cardiac positron emission tomography: state of the art. , 1991, Circulation.

[33]  M E Phelps,et al.  13N ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. , 1989, Circulation.

[34]  R. Ross.  The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.

[35]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[36]  K. Lipscomb,et al.  Effects of coronary stenoses on coronary flow reserve and resistance. , 1974, The American journal of cardiology.